Seven different formulae and agarose isoelectrofocusing (AIF) using immunolabelIing for IgG were compared for their ability to discriminate between intrathecally produced IgG and transudated IgG in cerebrospinal fluid. All reference limits were set to a specificity of 97' 5070 (reference group, n = 211). The probability of a positive test (p+) was evaluated for 112 patients with multiple sclerosis (MS), 42 with meningitis, 114 with noninflammatory diseases affecting the central nervous system (CNS), 23 with Guillairi-Barre syndrome, and 56 with various diseases not affecting the CNS. Agarose isoelectrofocusing had the best diagnostic sensitivity (93%) for MS, combined with a low p+ (0-19070) for other diseases. Among the formulae, the IgG extended index and Reiber's hyperbolic formula were equivalent, giving high (75-79%) diagnostic sensitivity for MS combined with low p ; (4-22%) for other diseases. All other formulae, although sensitive for MS, had a higher rate of false positive results.
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Intrathecal production of immunoglobulin G (IgG) is commonly associated with neuroinflammatory diseases such as multiple sclerosis (MS), and detection of such synthesis has long been an established diagnostic tool. 1 In cerebrospinal fluid (CSF) IgG derives not only from intrathecal synthesis (lgG;), but a large and varied amount derives from serum through transudation (lgG 1 ) . 2 Several formulae have appeared in order to discriminate IgG j from the total amount of IgG in CSF. 2, 3 Comparisons between such formulae have revealed that they have considerably different capabilities to detect IgG/-s Only one of these comparisons' covered the most recent formulae,6,7 but that study was not done according to the recommendations of the International Federation of Clinical Chemistry (IFCC),9 and it also included use of agarose isoelectric focusing (AIF) followed by silver Correspondence: Dr Sten Ohman. staining as a 'gold standard', instead of classification of the patients according to established clinical criteria.
Although AIF is considered to be the best indicator of IgG j,I,2 false positive as well as false negative findings occur using this test. Furthermore, AIF is a laborious and expensive method that may preclude widespread use. Consequently, there is a demand for quantitative methods. If such a method is used, it should be computed according to the formula showing the best diagnostic power for IgG j , that is with the highest true positive and the lowest false positive rates.
In this study we show how the choice of formula affects the diagnostic power of the test. AIF was included, not only as an independent reference method, but also to re-evaluate this test when applied to patients selected by clinical criteria.
MATERIAL AND METHODS
The following formulae were evaluated. (Noncommon abbreviations: CSF-IgG=lgG in CSF, CSF-Alb = albumin in CSF, S-IgG= IgG in serum, S-Alb = albumin in serum. All concentrations are in mg/L where not otherwise stated. a, b, c, and d are parameters of the equations.)
IgG index (IgG-I) 8 and IgG extended index (lgG-Elf (dimensionless): (CSF-IgG/S-IgG)/(CSF-Alb/S-Alb)Q where a = 1 for IgG-I, and a = 1 ·12 for IgG-EI.
Log IgG-index (IgG-LI)3 (dimensionless)
In [(CSF-IgG/S-IgG)/(CSF-Alb/S-Alb)] + 1 Reiber's hyperbolic formula (IgG-Hy)6 (mg/L of IgG j ) where a=0'43, b=O·OOl.
CSF and serum analysis
Determinations of albumin and IgG were performed by routine methods: laser nephelometry for CSF, and turbidimetry using a centrifugal analyser for serum.P These methods were analytically equivalent, but the more economic turbidimetric method used for serum was not sensitive enough for determination of IgG in CSF. Calibrator (N-Protein-Standard-Serum Catalogue No. OSAU 06/07) was purchased from Behringwerke AG (Marburg, Germany).
AIF using immunolabelling'! was performed to detect IgG bands in CSF and serum samples. CSF IgG bands were defined (unprejudiced by current definitions of 'oligoclonal' bands) as the number of bands present in CSF but not in the corresponding serum.
Some formulae were developed using analytical methods other than those in the present work.
Because the choice of method may affect the reults, the parameters (a,b,c,d) of the formulae were re-evaluated as in the original work, and corrected when appropriate.
Patients
A data base containing data from 610 requisitions for CSF protein analyses was collected. If a patient appeared more than once, the evaluations were performed on the first record (n = 428) where not otherwise stated. To increase the reliability of the reference limits? of the formulae, we added 130 patients (Partly lacking AIF data) from the reference group in an earlier study. 7 Hence, data from a total of 558 patients were evaluated.
The following groups of patients were studied: Reference group (n = 211): Patients retrospectively judged not to have any neurological disease affecting the CNS, e.g. tension headache, uncharacteristic dizziness, and mild psychoneurotic disorders. Multiple sclerosis (MS, n = 112): Patients fulfilling the criteria of definite MS.14 Meningitis (n = 42): Unspecified viral (n = 23), unspecified encephalitis (n = 4), Echo virus, herpes zoster, unspecified chronic meningitis (n = 3 each), Coxsackie virus (n = 2), borrelia, mumps, varicella, tick-borne encephalitis (n = 1 each). Non-inflammatory neurological and neoplastic diseases with CNS involvement (NON-INFL group, n = 114): Dementia (n = 28); cerebellar atrophy (n = 1); unspecified myelopathy (n = 3); TIA (n = 16), cerebral infarction (n = 25), subarachnoid haemorrhage (n = 12); Parkinson's disease (n = 4), Huntington's chorea (n = 1), other extrapyramidal syndromes (n = 3); non-Hodgkin's lymphoma (n = 12), chronic lymphatic leukaemia, Hodgkin's disease, monoclonal gammopathy of unknown significance, meningeal carcinomatosis, meningioma, cerebral metastases, tumor cerebri (n = 1 each); other non-inflammatory diseases (n = 2).
Guillain-Barre syndrome (GBS, n = 23): Two patients had the Fisher syndrome," four had chronic inflammatory demyelinating polyneuropathy as described by Dyck." The remaining 17 fulfilled the criteria of acute G~SY Diseases without CNS involvement (NON-CNS group, n = 56): Polyneuropathy (n = 10), peripheral facial palsy, vestibularis-disorder, mononeuropathia multiplex (n = 1 each); acute (n = 2), chronic (n = 1), and unspecified (n = 1) lymphatic leukaemia, non-Hodgkin's lymphoma (n = 10), Hodgkin's disease (n = 6), tumours (n = 7); chronic pain syndrome (n = 4), motor neurone disease, infection without CNS symptoms (n = 3 each), polymyositis, psychiatric disease, paraesthesiae, joint disease, essential tremor, haemifacialis spasm (n = 1 each).
Statistical methods
For each formula, a reference limit was set nonparametrically at the upper 2· 5 percentile of the reference group (n = 211) according to the recommendations of the IFCC. 9 Thus, the specificity was normalized to 97' 5l71o, so that the probability of a healthy person having a value above the reference range was 2· 5% for all formulae studied.
For each patient group and method (formula or AIF), the probability of a positive test (p+) and its 95% confidence range according to the binomial distribution was calculated. 18 To see if p+ differed significantly between methods the sign test" was used.
RESULTS
Parameters and reference ranges Parameter b in IgG-TO denotes the normal mean CSF/serum IgG ratio. Using our analytical methods this parameter was found to be 500, and not 369 as originally proposed." Correspondingly, in IgG-SC,4 parameter a (normal upper limit CSF-IgG) was 36, parameter b (normal mean CSF-Alb) was 189, and parameter c (equivalent transudation) was 94. These corrected parameters best satisfied the intentions of the original authors. Furthermore, a preliminary study indicated better diagnostic performance using them. All other parameters agreed with those of the original formulae.
Diagnostic sensitivity
The upper reference limits are listed in Table 1 . The probabilities of a positive test (p +) and their 95% confidence ranges are shown in Fig. 1 . For diseases characterized by intrathecal IgG synthesis, this parameter will ideally approach one, for other diseases and for the reference group it should be about 0'025 (2'5%).
In the reference group four to seven patients had a positive test by the formulae, compatible with a specificity of 97· 5% (Table 1 ). In Fig. 1 only one result is shown for this group because all formulae (and also the AIF method) had the same specificity by definition. (n+) and probability (p+) of a positive test. and its 95% confidence range according to the binomial distribution for seven formulae (n = 211). All reference ranges are compatible with 97·50/0 specificity according to [FCC recommendations. (See material and methods section for further explanation)
lntrathecally produced 19G
The reference limit is included in the reference range. "Parameters of the original formulae were modified, see text.
The best diagnostic sensitivity (93%) for MS was achieved with AIF, using 0-1 CSF IgG band as a reference range, i.e. if two or more bands were present in the CSF but not in the serum, the test was judged positive. The formulae yielded sensitivities between 73 and 88%, all but IgG-RE being significantly lower than that of AIF (Fig. 1) .
Eight patients with meningitis (19%) had oligoclonal (~2) CSF IgG bands by AIF indicating intrathecal IgG synthesis. Of these, one patient was examined almost a month after the onset of the symptoms, two were classified as chronic meningitis, one was caused by herpes zoster and one by Coxsackie B5 virus. The IgG-TO and IgG-RE formulae yielded higher p , than AIF and the other formulae ( Fig. 1) . Although almost the same number of patients had positive tests with IgG-EI, IgG-HY, IgG-Li and IgG-I ( Fig. 1 ) as with AIF, several patients had discordant tests, e.g. five patients with oligoclonal (~2) bands were negative by IgG-EI and four vice versa.
Patients with non-inflammatory and neoplastic diseases affecting the CNS (NON-INFL group) had a great number of diseases, but preliminary evaluation (not shown) indicated them to be statistically homogeneous so that the results could be pooled. Only four patients (3' 5%) had oligoclonal (~2) bands by AIF. All formulae except IgG-EI gave significantly higher p , values than AIF (Fig. 1) .
No patient with the Guillairi-Barre syndrome (GBS group) displayed CSF IgG bands by AIF. Several samples from each patient were available, but in none of a total of 45 determinations did CSF IgG bands occur. IgG-EI and IgG-HY
DISCUSSION
Detection and determination of intrathecally produced IgG and other immunoglobulins is of clinical interest in MS and other inflammatory diseases of the CNS, including CNS infections. I Although AIF or other electrophoretic techniques have long been considered the method of choice, such techniques are laborious and expensive. (In the second CEC Standards in Multiple Sclerosis workshop in G6ttingen in 1991, it was a majority consensus view that the information by immunofixation exceeds that of pure protein staining (silver stain). It should be emphasized that the results of the present study refers to such an immunofixation method, and consequently are not applicable to more nonspecific electrophoretic methods. It was also a consensus view that quantitation of IgG with suitable evaluation (Index, etc.) is part of a basic programme.) Furthermore, they need an experienced observer. An inexperienced viewer may not only overlook faint bands or bands in a polyclonal background, but also judge bands to be present where they are not, i.e, due to artefacts or bad matching of the quantities of serum and CSF IgG in the AIF gel.
In healthy individuals as well as in patients with blood-brain barrier damage a major part of IgG in CSF derives from serum by transudation. Several formulae for the assessment of intrathecally produced IgG in the presence of bloodbrain barrier damage have been evaluated.v? Such formulae may improve the cost-benefit performance for diagnosis of different neurological diseases.
When quantitative methods are used, correction for transudation has to be done using albumin as a marker of blood-brain barrier function. Recently we found that albumin and IgG transudation were not linearly correlated, and developed a new formula, IgG-EI,7 where the correction is progressively related to the CSFI serum albumin quotient. Another recent formula (lgG-HY) uses a hyperbolic equation for yielded p + = 0·22 in perfect concordance, whereas the other formulae gave higher p + values ( Fig. 1) .
Of patients with diseases not affecting the CNS (NON-CNS group), AIF revealed I patient (1' 8OJo) with oligoclonal (~2) bands. IgG-EI, IgG-I, IgG-LI and IgG-HY were equally sensitive, whereas the other formulae rendered significantly higher p + values (Fig. 1) . the same reason." IgG-LI is not a true non-linear correction for albumin transport, but rather a mathematical transformation of IgG-L Since neither logarithmic transformation nor addition of a constant affects the position in a sorted list, IgG-LI gives identical results to IgG-I when using non-parametric statistics. In a previous report only a preliminary evaluation of the diagnostic value of IgG-EI was possible because of a limited number of patients." In the present study all commonly used formulae, as well as AIF, were compared using the analytical results of 558 patients with clinically established neurological and non-neurological diseases. None of these patients appeared in our first report," except for 130 patients in the reference group.
In the present study, all but the IgG-RE formula showed significantly lower sensitivity for MS than AIF. However, IgG-RE also had the highest rate of false positive tests as indicated by the p + for diagnoses not expected to have intrathecal IgG synthesis.
About 100/0 of the MS patients had oligoclonal (~2) CSF IgG bands without a positive test by any formula. The diagnostic sensitivity of AIF depends on how 'oligoclonal' is defined. Literally (and also in the meaning generally used) oligoclonal means 'two or more' bands present in CSF, but not in serum. Because different AIF methods may be more or less capable of displaying the bands, we also tested other criteria. Using the common definition the sensitivity for MS was 93% (Fig. 1) , but using~3 bands, as recommended for a similar AIF method;'? the sensitivity decreased to 890/0. For the reference group, one of 81 patients (I' 2%) had oligoclonal bands according to both definitions, which is within the 95% confidence range for 97' 5% specificity.
In a limited number of patients, well-established oligoclonal bands appeared despite formula values welI within the reference range. Making the formulae more sensitive and less specific by decreasing the reference limits yielded no improvement. If, for example, the reference limit of IgG-EI was set to O·99 instead of I . 24 the test became equally as sensitive as AIF for MS. However, with such a low reference limit, 19% of the reference group and 29-50% of the other non-MS groups had positive tests. The other formulae showed a similar pattern.
For patients without central nervous inflammatory diseases (NON-INFL, GBS, and NON-CNS groups) IgG-EI and IgG-HY gave con- Considering that the binomial test on such great a number is very sensitive for small differences, these formulae were clinically equivalent. However, IgG-EI is a simpler formula than IgG-HY and should therefore be preferred.
In the Guillairi-Barre syndrome a characteristic feature is pronounced blood-brain barrier damage. However, intrathecal IgG synthesis has been proposed in about 20% of such patients.?
Although the presence of CSF oligoclonal IgG bands may have been masked by a high polyclonal IgG concentration, the fact that none of the patients revealed such bands indicated that intrathecal IgG synthesis seldomly occur in Guillairi-Barre syndrome.
In meningitis patients, AIF was the most sensitive method for detecting intrathecal IgG synthesis. However, IgG-EI, IgG-I, and IgG-HY, gave similar P+, and these formulae may be sufficiently sensitive for routine use. Discordant results by AIF and quantitative determinations indicated that CSF IgG bands may occur without a concomitant increase in CSF IgG concentration. Possibly the overall (polyclonal) IgG level was low in these cases, masking an increase of specific oligoclonal IgG bands.
Another source of discord between AIF and quantitative methods is that oligoclonal bands may remain several years after recovery from, for example, a meningitis-" that may have passed undiagnosed. In cases with low polyclonal IgG concentration, these bands may be easily detected, although the concentration of oligo clonal IgG is low. This is a possible source of oligoclonal bands in healthy people and people without neuroinflammatory diseases.
In conclusion, in MS all formulae gave slightly lower diagnostic sensitivity than AIF using immunolabelling of IgG bands. Thus, although laborious and expensive, this kind of AIF remains the method of choice in patients with an unknown diagnosis and a suspicion of a neuroinflammatory disease such as MS. For other neurological diseases such as meningitis, and probably in follow-up cases, IgG-EI or IgG-HY should be sufficiently sensitive. Compared with IgG-I and the other formulae, IgG-EI and IgG-HY showed the best combination of a high sensitivity to central nervous inflammatory diseases and a low rate of false positive findings. Of these two formulae, IgG-EI is simpler, and is therefore preferred.
